# Triple Negative Breast Cancer and Celecoxib. Pilot Study

> **NCT07104266** · PHASE2 · RECRUITING · sponsor: **Université de Sherbrooke** · enrollment: 30 (estimated)

## Conditions studied

- Triple-Negative Breast Cancer

## Interventions

- **DRUG:** Celecoxib (Celebrex)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07104266
- **Lead sponsor:** Université de Sherbrooke
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-04
- **Primary completion:** 2028-08-04
- **Final completion:** 2032-08-04
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07104266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07104266, "Triple Negative Breast Cancer and Celecoxib. Pilot Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07104266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*